Rani Therapeutics
RANI
68 hedge funds and large institutions have $34.7M invested in Rani Therapeutics in 2026 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 16 closing their positions.
50% more call options, than puts
Call options by funds: $24K | Put options by funds: $16K
11% more capital invested
Capital invested by funds: $31.4M → $34.7M (+$3.31M)
2.84% more ownership
Funds ownership: 42.86% → 45.7% (+2.8%)
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
8% less funds holding
Funds holding: 74 → 68 (-6)
31% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 16
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$2.06M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$1.66M |
| 3 |
AIC
AWM Investment Company
New York
|
+$887K |
| 4 |
HCM
Heights Capital Management
San Francisco,
California
|
+$829K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$569K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$358K |
| 2 |
Millennium Management
New York
|
-$298K |
| 3 |
BlackRock
New York
|
-$190K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$116K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$113K |
RANI Hedge Fund Activity: Q2 2026 in Review
68 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q2 2026, worth a combined $34.7M — up 11% from $31.4M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of RANI and 11 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 15 added.
The largest buyer was Polar Asset Management Partners, opening a new position worth an estimated $2.06M. The largest seller was 683 Capital Management, exiting entirely with an estimated $358K sold.
- 68 institutional investors held Rani Therapeutics (RANI) as of Q2 2026, down from 74 in Q1 2026.
- Funds reported $34.7M of Rani Therapeutics stock for Q2 2026, up 11% quarter-over-quarter.
- 11 funds opened new Rani Therapeutics positions in Q2 2026 and 16 closed out, a net change of -5 holders.
- The largest Rani Therapeutics buyer in Q2 2026 was Polar Asset Management Partners, an estimated $2.06M added.
- The largest Rani Therapeutics seller in Q2 2026 was 683 Capital Management, an estimated $358K sold.
Based on aggregated 13F filings for Q2 2026.